5 results on '"El-Karak, Fadi"'
Search Results
2. Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients.
- Author
-
Assi, Hazem I., Alameh, Ibrahim A., Khoury, Jessica, Abdul Halim, Nour, El Karak, Fadi, Farhat, Fadi, Berro, Juliett, Sbaity, Eman, Charafeddine, Maya, Tfayli, Arafat, Salem, Ziad, and El Saghir, Nagi
- Subjects
TUMOR classification ,GENOMICS ,CANCER patients ,ADJUVANT chemotherapy ,BREAST cancer - Abstract
Introduction. Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and having reliable prognostic factors could significantly improve rates of appropriate treatment administration. In this study, we showcase the impact of genomic tests on adjuvant treatment decisions in EBC patients. Materials and Methods. This is a retrospective study that includes EBC patients treated between December 2016 and February 2018. The physician's choice of treatment was recorded before and after obtaining the results of the genomics tests. Baseline demographics and pathological data were collected from medical records. Results. A total of 75 patients were included. Fifty patients underwent Oncotype DX genomic analysis, 11 patients underwent Prosigna analysis, and 14 patients underwent Endopredict analysis. A total of 21 physicians' plans (28%) were initially undecided and then carried out after obtaining genomic test results. 13 patients were planned to undergo endocrine therapy alone, while 8 were planned to undergo both endocrine therapy and chemotherapy. Treatment was changed in 26 patients (34.67%). The decision to deescalate therapy was taken in 19 patients (25.33%). The decision to escalate treatment was made in 7 patients (9.33%). Conclusion. Our study demonstrates the importance of genomics testing, as it assisted physicians in avoiding unnecessary adjuvant chemotherapy in 25.33% of patients, thus reducing side effects of chemotherapy and the financial burden on patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience.
- Author
-
Assi, Tarek, Kattan, Joseph, El Rassy, Elie, Tabchi, Samer, Chebib, Ralph, Moussa, Tania, Hanna, Colette, El Karak, Fadi, Farhat, Fadi, and Ghosn, Marwan
- Subjects
HORMONE receptor positive breast cancer ,EVEROLIMUS ,CANCER-related mortality ,HORMONE therapy ,HORMONE resistance ,RAPAMYCIN ,EXEMESTANE - Abstract
Introduction: Breast cancer is the second leading cause of cancer-related mortality despite the staggering improvement in cancer therapeutics. So far, published data illustrate endocrine therapy as the cornerstone treatment for patients with hormone receptor-positive metastatic breast cancer. Unfortunately, most patients eventually develop resistance to this treatment.Methods: The purpose of this study is to evaluate the efficacy of mammalian target of rapamycin inhibition in reversing hormone resistance in the Lebanese breast cancer patients. Efficacy of the intervention according to the independent factors and notable side effects encountered were the primary points of the evaluation.Results: In total, fifty patients received the combination of everolimus and exemestane. The mean age of the study population was 61 ± 11 years. Sensitivity to hormonal therapy before the start of the combination treatment was estimated at 64%. Response rate was 14%, and all patients were partial responders. After regular interval evaluation, the median progression-free survival was 5.2 months since the initiation of therapy. The main toxicities associated with the combination were stomatitis (22%), myalgia (22%), skin toxicity (8%), and hyperglycemia (4%), all Grades 1 and 2.Conclusion: Everolimus has been shown to be effective in overcoming hormonal resistance in Lebanese breast cancer patients with results inferior to those reported in the BOLERO-2 population. The particular differences in molecular and pathological aspects of breast cancer in our region should stimulate the extensive research for a better understanding of the particular pattern of the disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience.
- Author
-
El Rassy, Elie, Ghosn, Marwan, Farhat, Fadi, Bakouny, Ziad, Assi, Tarek, Chahine, Georges, Nasr, Fadi, Haddad, Fady Ghassan, El Karak, Fadi, and Kattan, Joseph
- Subjects
BREAST tumors ,COMBINED modality therapy ,DRUG toxicity ,EXPERIENCE ,LONGITUDINAL method ,DOCETAXEL - Abstract
The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer.Background: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012.Methods: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common.Results: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients. [ABSTRACT FROM AUTHOR]Conclusion: - Published
- 2018
- Full Text
- View/download PDF
5. Triple-Negative Breast Cancer in Lebanon: A Case Series.
- Author
-
GHOSN, MARWAN, HAJJ, CARLA, KATTAN, JOSEPH, FARHAT, FADI, EL KARAK, FADI, NASR, FADI, ABADJIAN, GERARD, and CHAHINE, GEORGES
- Subjects
ANALYSIS of variance ,BREAST tumors ,CANCER chemotherapy ,CONFIDENCE intervals ,MASTECTOMY ,PROBABILITY theory ,SURVIVAL analysis (Biometry) ,TUMOR classification ,PHENOTYPES - Abstract
Objectives. To determine the incidence, characteristics, and survival outcomes of triple-negative breast cancer patients in a medical oncology practice in Lebanon. Methods. The pathology reports of all breast cancer cases diagnosed or treated in 1997-2008 were reviewed. Results. One hundred seventy breast cancer cases (9.3%) of the 1,834 cases that were identified in this practice over a 10-year span had a triple-negative phenotype, with a median age at diagnosis of 52 years. The pathology distribution of those cases was as follows: invasive ductal carcinoma, 85%; medullary carcinoma, 5%; invasive lobular carcinoma, 5%; 95 cases (63%) were grade III. At diagnosis, 17% presented with stage I, 47% had stage II, 24% had stage III, and 12% had stage IV disease, whereas 11% had an inflammatory component. After a median follow- up of 17 months, 43 patients (25.3%) had relapsed and the most common sites of relapse were the brain (19%), lungs (19%), and bones (12%). The risk for recurrence peaked at 1.5 years and became almost nil after 3 years. Twenty patients received induction chemotherapy, among whom six (42.9%) had a complete response and six (42.9%) had a partial response to treatment. None of the patients progressed on neoadjuvant chemotherapy. The 5-year disease- free survival rate was 75% for stage I, 58% for stage II, and 40% for stage III patients, whereas the 5-year overall survival rate was 88% for stage I, 72% for stage II, and 63% for stage III patients. Adjuvant therapy was administered to 96% of patients, using a taxane-based regimen in 38% of cases. The median survival time for stage IV patients was 19 months, with a first line taxane-based regimen used in 50% of cases. Conclusions. The incidence of triple-negative breast cancer in Lebanon is similar to that described in the literature. In order to determine targets for future therapeutic options, it is essential to understand the biology of this particular breast cancer subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.